A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 151,900 shares of CAPR stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151,900
Previous 36,700 313.9%
Holding current value
$2.9 Million
Previous $175,000 1220.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.63 - $7.09 $167,193 - $256,026
36,111 Added 117.23%
66,914 $319,000
Q1 2024

May 15, 2024

BUY
$3.61 - $6.88 $111,198 - $211,924
30,803 New
30,803 $209,000
Q3 2023

Nov 14, 2023

SELL
$3.42 - $7.85 $84,771 - $194,577
-24,787 Reduced 54.3%
20,861 $71,000
Q2 2023

Aug 14, 2023

BUY
$3.76 - $5.05 $115,326 - $154,893
30,672 Added 204.81%
45,648 $218,000
Q1 2023

May 15, 2023

SELL
$3.78 - $5.03 $46,626 - $62,045
-12,335 Reduced 45.16%
14,976 $63,000
Q4 2022

Feb 14, 2023

SELL
$3.36 - $6.55 $29,994 - $58,471
-8,927 Reduced 24.63%
27,311 $105,000
Q3 2022

Nov 14, 2022

SELL
$3.61 - $6.08 $38,316 - $64,533
-10,614 Reduced 22.65%
36,238 $217,000
Q2 2022

Aug 15, 2022

SELL
$2.89 - $4.51 $33,971 - $53,015
-11,755 Reduced 20.06%
46,852 $163,000
Q1 2022

May 16, 2022

SELL
$2.83 - $5.68 $60,083 - $120,592
-21,231 Reduced 26.59%
58,607 $201,000
Q4 2021

Feb 14, 2022

SELL
$2.89 - $4.16 $91,647 - $131,921
-31,712 Reduced 28.43%
79,838 $233,000
Q3 2021

Nov 15, 2021

BUY
$3.8 - $5.23 $159,185 - $219,089
41,891 Added 60.14%
111,550 $448,000
Q2 2021

Aug 16, 2021

BUY
$3.16 - $5.72 $73,820 - $133,624
23,361 Added 50.46%
69,659 $357,000
Q1 2021

May 17, 2021

BUY
$3.63 - $7.93 $34,829 - $76,088
9,595 Added 26.14%
46,298 $217,000
Q4 2020

Feb 16, 2021

BUY
$3.43 - $5.23 $4,308 - $6,568
1,256 Added 3.54%
36,703 $126,000
Q3 2020

Nov 16, 2020

BUY
$4.08 - $9.81 $20,783 - $49,972
5,094 Added 16.78%
35,447 $186,000
Q2 2020

Aug 14, 2020

BUY
$1.0 - $8.5 $6,474 - $55,029
6,474 Added 27.11%
30,353 $140,000
Q1 2020

May 15, 2020

BUY
$0.94 - $2.02 $11,730 - $25,207
12,479 Added 109.46%
23,879 $28,000
Q4 2019

Feb 14, 2020

BUY
$1.04 - $3.55 $11,856 - $40,470
11,400 New
11,400 $15,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $465M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.